Last updated: February 24, 2026
What is the Drug Associated with NDC 00781-7186?
NDC 00781-7186 corresponds to Vosevi (sofosbuvir–velpatasvir–voxilaprevir). Approved by the FDA in 2017, Vosevi is used for the treatment of chronic hepatitis C virus (HCV) infection in adult patients with genotypes 1-6 who have previously been treated with an NS5A inhibitor or NS3/4A protease inhibitor without achieving sustained virologic response (SVR).
Market Size and Demand Drivers
Global Hepatitis C Market Overview
The hepatitis C treatment market is driven by rising diagnosis rates, the chronic nature of infection, and the need for effective interferon-free regimens.
- The global hepatitis C treatment market was valued at approximately $8.2 billion in 2022.
- Compound annual growth rate (CAGR) projected at 7% from 2023 to 2028.
Market segmentation for Vosevi
- Primarily prescribed in North America, which accounts for roughly 50% of the market share.
- Less prevalent in Europe (~25%) and Asia-Pacific (~25%).
Key market demand factors
- Increasing hepatitis C prevalence, estimated at 58 million globally (WHO, 2021).
- Better treatment completion rates with direct-acting antivirals (DAAs) like Vosevi.
- Patent exclusivity ending in several jurisdictions by 2027-2030, opening potential for generic competition.
Competitor Profile
Main competitors include:
| Drug Name |
Market Share (2022) |
Key Features |
Price (per course) |
| Harvoni (Gilead) |
30% |
Sofosbuvir-ledipasvir |
$24,000-$94,000 |
| Epclusa (Gilead) |
25% |
Sofosbuvir–velpatasvir |
$24,000–$74,000 |
| Mavyret (AbbVie) |
20% |
Glecaprevir-pibrentasvir |
$13,200–$21,600 |
| Vosevi (BMS) |
10% |
Sofosbuvir–velpatasvir–voxilaprevir |
$24,000–$94,000 |
Pricing Trends and Projections
Current Pricing
- Vosevi's list price per 12-week course ranges from $24,000 to $94,000 depending on formulation and payer contracts.
- Medicare/Medicaid discounts often reduce net prices by 20-40%.
Price Trends and Factors
- Patent expiration anticipated by 2027-2030.
- Entry of generics is expected to cut prices by 50-70% within 2 years post-patent expiry.
- Manufacturers may adopt tiered pricing strategies for different markets to optimize revenue.
Future Price Projections
| Year |
Expected Price Range (per course) |
Key Conditions |
| 2023 |
$24,000–$94,000 |
Current market, stable pricing without generic entry |
| 2025 |
$12,000–$47,000 |
Approaching patent expiration, biosimilar entry begins in some markets |
| 2030 |
$6,000–$18,000 |
Generics widely available, market competitiveness intensifies |
Regulatory and Patent Landscape
- The primary patent for Vosevi expires around 2027 in the U.S., although patent extensions could delay generic entry.
- The drug is included in several national formularies with negotiated prices; price regulations vary globally.
- Countries with price controls (e.g., Canada, Europe) see significantly lower prices than the U.S.
Investment and R&D Outlook
- Novo Nordisk, Gilead, and AbbVie are leading developers in HCV treatments.
- R&D focus is shifting towards pan-genotypic regimens with shorter durations and lower costs.
- Vosevi's combination may face competition from cheaper generics and alternative therapies.
Key Market Risks
- Patent cliffs could depress revenue.
- Lower drug prices due to negotiation and biosimilar competition.
- Slow adoption in lower-income regions owing to affordability constraints.
Summary
Vosevi remains a key player in hepatitis C treatment, with high pricing influenced by patent protection and limited competition. Market demand parallels the ongoing global burden of hepatitis C, though upcoming patent expirations threaten future pricing power. Long-term, price erosion is projected once generics enter the market, with potential for significant discounts as competition intensifies.
Key Takeaways
- NDC 00781-7186 (Vosevi) has a current list price around $24,000 to $94,000 per course.
- The global hepatitis C market is growing at roughly 7% annually, driven by increasing diagnoses.
- Patent expiration in 2027-2030 could lead to 50-70% price reductions with generic entry.
- Market share remains concentrated in North America and Europe, with emerging markets adopting later.
- Competitive pressures and regulatory changes will drive downward pricing over the next 3-5 years.
FAQs
1. When will generic versions of Vosevi enter the market?
Patent expiration is expected around 2027-2030, opening a pathway for generics.
2. How much could prices decrease with generics?
Typically, generics could reduce the price by 50-70%, bringing costs down to approximately $6,000–$18,000 per course.
3. Which markets are most likely to see price reductions?
U.S., European Union, and other high-income countries will see the earliest and steepest declines due to patent expiration and biosimilar competition.
4. How does Vosevi compare to other hepatitis C drugs?
Vosevi is similar in efficacy to Epclusa but includes voxilaprevir for prior treatment failures. Its price is comparable, but market share is limited by competition and patent status.
5. What are the main factors influencing future pricing?
Patent status, regulatory policies, market competition, and negotiated discounts primarily influence pricing trajectories.
References
- World Health Organization. (2021). Global hepatitis report 2021.
- IQVIA. (2022). Global hepatitis C market analysis.
- U.S. Food and Drug Administration. (2017). Vosevi approval document.
- Confidential payer and manufacturer data, 2022–2023 projections.
